Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.
M Chen, V O Ona, M Li, R J Ferrante, K B Fink, S Zhu, J Bian, L Guo, L A Farrell, S M Hersch, W Hobbs, J P Vonsattel, J H Cha, R M Friedlander
Neuroapoptosis Laboratory, Neurosurgical Service, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Nature medicine 2000 JulHuntington disease is an autosomal dominant neurodegenerative disease with no effective treatment. Minocycline is a tetracycline derivative with proven safety. After ischemia, minocycline inhibits caspase-1 and inducible nitric oxide synthetase upregulation, and reduces infarction. As caspase-1 and nitric oxide seem to play a role in Huntington disease, we evaluated the therapeutic efficacy of minocycline in the R6/2 mouse model of Huntington disease. We report that minocycline delays disease progression, inhibits caspase-1 and caspase-3 mRNA upregulation, and decreases inducible nitric oxide synthetase activity. In addition, effective pharmacotherapy in R6/2 mice requires caspase-1 and caspase-3 inhibition. This is the first demonstration of caspase-1 and caspase-3 transcriptional regulation in a Huntington disease model.
Citation
M Chen, V O Ona, M Li, R J Ferrante, K B Fink, S Zhu, J Bian, L Guo, L A Farrell, S M Hersch, W Hobbs, J P Vonsattel, J H Cha, R M Friedlander. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature medicine. 2000 Jul;6(7):797-801
Mesh Tags
Substances
PMID: 10888929
View Full Text
